Search peptides, terms, sources/
Hormonal signalling

Kisspeptin

Also known as: Metastin · kisspeptin-54 · kisspeptin-10

Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

5 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Kisspeptin is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials5 human trials · 1 animal

What is Kisspeptin?

Kisspeptin is a natural hormone that triggers release of gonadotropin-releasing hormone, studied in UK trials for hypoactive sexual desire disorder and for triggering egg maturation in IVF. No UK marketing authorisation has been identified, and the evidence comes from a small number of randomised trials run at Imperial College London sites.

It is encoded by the KISS1 gene and acts on the KISS1R receptor (also called GPR54) in the hypothalamus, causing pulses of gonadotropin-releasing hormone (GnRH). The IVF trials were in women at high risk of ovarian hyperstimulation syndrome.

Class
Neuropeptide Hormone (RFamide Family)
Origin
Endogenous
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Kisspeptin work?

Kisspeptin binds a receptor on brain cells in the hypothalamus, which then release gonadotropin-releasing hormone. This drives the pituitary gland to release hormones that control the ovaries and testes. In trials it also changed activity in brain areas linked to sexual response.

The mechanism in more detail

Kisspeptin binds KISS1R on GnRH neurons in the hypothalamus, signalling through the phospholipase C pathway to trigger pulsatile GnRH release. This drives downstream luteinising hormone (LH) and follicle-stimulating hormone (FSH) secretion from the anterior pituitary, and consequently gonadal steroid production, forming the mechanistic basis for its investigational use as an IVF oocyte-maturation trigger in women at high risk of ovarian hyperstimulation syndrome.

In randomised controlled human trials, kisspeptin administration has also been shown to modulate activity in brain regions involved in sexual and attraction processing, including the anterior cingulate cortex, hippocampus, parahippocampus and posterior cingulate, independently of, or alongside, its effects on the hypothalamic-pituitary-gonadal axis. These trials, conducted in men and women with diagnosed hypoactive sexual desire disorder, reported changes in brain activity and, in the male trial, increased penile tumescence in response to sexual visual stimuli, relative to placebo.

Kisspeptin has also been investigated for a possible role in appetite and food intake. A controlled human trial in women with overweight or obesity found no significant effect on hunger, food intake, fullness, or glucose and insulin levels compared with a vehicle control, a genuine null result that should not be read as evidence of a metabolic or weight-management benefit.

Mechanisms and targets

Central Neuromodulation (Sexual/Attraction Processing)GPCR Agonism (KISS1R/GPR54)HPG-Axis / GnRH-Pulse StimulationKISS1R (GPR54)

Classification and structure

Names
Kisspeptin; Metastin; kisspeptin-54 (KP54); kisspeptin-10 (KP10); kisspeptin-14; kisspeptin-13
Class
Neuropeptide Hormone (RFamide Family)
Origin
Endogenous
Structure
KISS1 encodes a 145-amino-acid precursor (prepro-kisspeptin), cleaved into peptides of varying length that all share the same C-terminal decapeptide sequence (kisspeptin-10), sufficient to bind and activate KISS1R. The most abundant circulating cleavage product is the 54-amino-acid form (kisspeptin-54, molecular weight approximately 5857.5 g/mol).
Routes used in the research
Intravenous infusion in the hypoactive sexual desire disorder and food-intake trials; subcutaneous injection in the IVF oocyte-maturation trials. Both were given under clinical supervision in trial settings.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Kisspeptin has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
15000

Male HSDD crossover trial Limited

In a randomised, double-blind, placebo-controlled, two-way crossover trial of 32 men with hypoactive sexual desire disorder (HSDD), intravenous kisspeptin-54 significantly modulated activity in brain structures involved in sexual processing compared with placebo, and increased penile tumescence in response to sexual visual stimuli by up to 56% relative to placebo.

Study type
Human trial
Population
32 heterosexual men (mean age 37.9 years) with diagnosed HSDD, Imperial College Healthcare NHS Trust, London
Source
1 Mills et al., 2023

Limitation: Single trial, not yet independently replicated; authors describe it as first evidence; crossover design with washout, not a large parallel-group trial.

Female HSDD neuroimaging trial Limited

In a randomised, double-masked, placebo-controlled, two-way crossover trial of 32 premenopausal women with HSDD, intravenous kisspeptin-54 modulated sexual- and attraction-related brain processing on functional neuroimaging, with kisspeptin-enhanced hippocampal activity during erotic-video viewing positively correlating with baseline sexual-function-related distress, and increased posterior cingulate activity correlating with reduced sexual aversion.

Study type
Human trial
Population
32 premenopausal women (mean age 29.2 years) with HSDD, UK university research setting
Source
2 Thurston et al., 2022

Limitation: Results apply only to premenopausal women; perimenopausal women, postmenopausal women and men were not studied; correlational brain-behaviour findings, not a direct behavioural outcome; single research-imaging setting may not reflect naturalistic contexts.

Oocyte maturation in IVF Limited

In a Phase 2, multi-dose, open-label randomised controlled trial of 60 women at high risk of ovarian hyperstimulation syndrome (OHSS) undergoing IVF, a single subcutaneous injection of kisspeptin-54, with the amount adjusted to each woman's risk, triggered oocyte maturation in 95% (57/60) of women, with clinical pregnancy and live birth rates per transfer of 52.9% and 45.1% respectively, and no cases of moderate, severe or critical OHSS.

Study type
Human trial
Population
60 women aged 18 to 34 at high OHSS risk, Hammersmith Hospital IVF unit, London
Source
3 Abbara et al., 2015

Limitation: Single-centre; small sample per dose-arm; no direct head-to-head comparison with standard triggers in this trial; unclear whether pregnancy rates are replicable under different luteal-support regimens, per the authors' own stated limitation.

Repeat injection, 62 women Limited

In a Phase 2 randomised, placebo-controlled trial of 62 women at high OHSS risk, a second kisspeptin-54 dose given 10 hours after the first increased the proportion achieving 60% or greater oocyte yield from 45% (single dose) to 71% (double dose), and live birth rate from 19.4% to 39%. Moderate OHSS occurred in one patient in the single-dose arm (1.6%) and mild OHSS in one patient in the double-dose arm (1.6%); the second dose did not increase OHSS incidence.

Study type
Human trial
Population
62 women aged 18 to 34 at high OHSS risk, Hammersmith Hospital IVF unit, London
Source
4 Abbara et al., 2017

Limitation: Single dose-interval tested; oocyte retrieval timing may not capture the full benefit window per authors; underpowered for implantation-rate comparisons; shares substantially the same investigator group, hospital site and target population as the single-dose trial above, so does not by itself clear the bar for independent replication.

No effect on food intake Limited

In a single-blinded, randomised-order crossover trial of 17 women with overweight or obesity, a 120-minute intravenous kisspeptin-54 infusion, with a meal provided at 45 minutes, did not significantly affect self-rated hunger, food intake (6.2 versus 6.8 kcal/kg, p=0.33), fullness, eating pleasure, or glucose and insulin levels compared with vehicle control.

Study type
Human trial
Population
17 women (mean age 49.2 years, BMI 34.3 kg/m2), UK
Source
5 Izzi-Engbeaya et al., 2023

Limitation: Short (120-minute) exposure window; insufficient power for subgroup analyses; this is a genuine negative or null finding and does not support a weight-management or appetite-suppression claim.

Contested tumour-biology literature Preliminary

Preclinical and mechanistic literature describes KISS1/kisspeptin signalling as originally identified as a metastasis-suppressor system, reducing metastatic potential via E-cadherin regulation and MMP9 suppression, and inhibiting cellular migration and invasion in several cancer types via KISS1R-Gq-PKC signalling. Subsequent literature explicitly characterises the role of kisspeptin/KISS1R in tumour biology as controversial, with some evidence of pro-tumorigenic and drug-resistance-promoting effects, for example in triple-negative breast cancer, depending on cancer type, stage and receptor status.

Study type
Animal
Population
Cell-line and preclinical cancer models (breast, colorectal, melanoma) across multiple studies reviewed
Source
6 Fratangelo et al., 2018

Limitation: In-vitro and preclinical evidence only; no human oncology trial data identified; effects reported are cancer-type and stage dependent and in places contradictory across the underlying primary studies the review pools.

What safety findings have been reported?

5 safety findings are recorded for Kisspeptin. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Male HSDD trial adverse events

32 men were given kisspeptin in a randomised trial for low sexual desire. No side effects or adverse events were reported. There was no significant effect on blood pressure or heart rate. Some participants reported more flushing as part of the study's own measures, which the authors did not class as an adverse event. The trial was too small to rule out rarer harms.

Source
1 Mills et al., 2023

Female HSDD trial adverse events

32 women were given kisspeptin in a randomised trial for low sexual desire. No adverse effects were reported. Small rises in luteinising hormone and follicle-stimulating hormone showed the dose was biologically active. The trial was too small to rule out rarer harms.

Source
2 Thurston et al., 2022

IVF trial complications, 60 women

60 women at high risk of ovarian hyperstimulation syndrome (OHSS) were given kisspeptin-54 by injection in an IVF trial. No moderate, severe or critical OHSS occurred. Reported complications were 2 ectopic pregnancies, 3 miscarriages and 1 stillbirth, which the authors described as known IVF complications and did not attribute to kisspeptin. The trial was too small to rule out rarer harms.

Source
3 Abbara et al., 2015

OHSS incidence, repeat injection

62 women at high OHSS risk were given one or two doses of kisspeptin-54 in a follow-on IVF trial. Moderate OHSS occurred in 1 of 31 women given one dose and mild OHSS in 1 of 31 given two doses; the second dose did not increase OHSS. The trial was too small to rule out rarer harms.

Source
4 Abbara et al., 2017

No side effects reported

No side effects were reported by participants in the 17-woman food-intake crossover trial; heart rate and blood pressure were unaffected.

Source
5 Izzi-Engbeaya et al., 2023

What is Kisspeptin's UK regulatory status?

Marketing authorisation
No UK marketing authorisation for any kisspeptin-containing product. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for kisspeptin or metastin.
Prescription status
Not applicable, no licensed UK product was found to classify. Not available as a prescribable medicine in UK clinical practice outside a clinical trial.
Medicine class
Not a licensed medicine in the UK. Used exclusively as an investigational medicinal product (IMP) within authorised clinical trials (CTIMPs).
MHRA position
Investigational Medicinal Product (IMP) under UK Clinical Trial Authorisation (CTA), studied at Imperial College Healthcare NHS Trust sites under the Medicines for Human Use (Clinical Trials) Regulations 2004 as amended. Kisspeptin's UK human use identified in the sources has occurred within MHRA-authorised, ethics-committee-approved clinical trials.
Authorised use
None. No UK-approved therapeutic indication exists; all cited findings are investigational trial results.
Research use
Actively studied as an investigational compound in formal, MHRA-authorised UK clinical trials (Imperial College London and Imperial College Healthcare NHS Trust), publicly and charitably funded (Medical Research Council, Wellcome Trust, National Institute for Health Research).
Other restrictions
No MHRA public safety notice naming kisspeptin has been identified. Supply of an unlicensed substance for human use outside an authorised clinical trial, or outside the Human Medicines Regulations 2012 specials import route (SI 2012/1916, Regulation 167), would itself be unlawful; this is a general framework fact, not a kisspeptin-specific enforcement action. In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names kisspeptin and its agonist analogues under S2.2.1, testosterone-stimulating peptides in males.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Kisspeptin is recorded as not licensed in the UK (checked 14 November 2026).

References

7 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Mills EG, Ertl N, Wall MB, et al. (2023). Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network OpenHuman clinical trial, RCT · DOI 10.1001/jamanetworkopen.2022.54313 · PMID 36735255 · Original ↗
  2. Thurston L, Hunjan T, Ertl N, et al. (2022). Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network OpenHuman clinical trial, RCT · DOI 10.1001/jamanetworkopen.2022.36131 · PMID 36287566 · Original ↗
  3. Abbara A, Jayasena CN, Christopoulos G, et al. (2015). Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. The Journal of Clinical Endocrinology & MetabolismHuman clinical trial, RCT · DOI 10.1210/jc.2015-2332 · PMID 26192876 · Original ↗
  4. Abbara A, et al. (Dhillo WS group) (2017). A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Human ReproductionHuman clinical trial, RCT · DOI 10.1093/humrep/dex253 · Original ↗
  5. Izzi-Engbeaya C, et al. (2023). The effects of kisspeptin on food intake in women with overweight or obesity. Diabetes, Obesity & MetabolismHuman clinical trial, RCT · DOI 10.1111/dom.15086 · PMID 37039248 · Original ↗
  6. Fratangelo F, Carriero MV, Motti ML (2018). Controversial Role of Kisspeptins/KiSS-1R Signaling System in Tumor Development. Frontiers in EndocrinologyAnimal-preclinical, In-vitro, Narrative review · DOI 10.3389/fendo.2018.00192 · PMID 29760678 · Original ↗
  7. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Kisspeptin

What is Kisspeptin?

Kisspeptin is a natural hormone that triggers release of gonadotropin-releasing hormone, studied in UK trials for hypoactive sexual desire disorder and for triggering egg maturation in IVF. No UK marketing authorisation has been identified, and the evidence comes from a small number of randomised trials run at Imperial College London sites. Read what it is.

Is Kisspeptin licensed in the UK?

PeptGuru records Kisspeptin's UK status as: Not licensed in the UK. No UK marketing authorisation for any kisspeptin-containing product. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Kisspeptin show?

PeptGuru records 6 research findings for Kisspeptin: 5 from human trials and 1 from an animal study. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Kisspeptin?

5 safety findings are recorded, including: male HSDD trial adverse events; female HSDD trial adverse events; IVF trial complications, 60 women. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Kisspeptin?

All 7 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · UK status confirmed by a dated MHRA database check (no kisspeptin product found). WADA 2026 listing added.

How findings are graded: the grading method. All changes.

  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • CagrilintideAM833

    Not licensed in the UK. Investigational long-acting amylin analogue studied for weight management, alone and with semaglutide.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK

Compare Kisspeptin with AOD-9604

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.